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SUMMARY
Background
The extent to which potentially curative therapies are used in patients with hepa-
tocellular cancer (HCC) and their related outcomes are unknown in the US.
Aim
To determine the rate and outcomes of potentially curative treatment in
patients with HCC.
Methods
Eleven US centers followed patients with HCC between 2001 and 2007. We
determined rates of liver transplantation, surgical resection, or tumour
ablation during follow-up, examined differences in adjusted survival of
patients receiving these treatments, and determined the factors associated
with receipt of potentially curative treatment.
Results
Of the 267 patients, 76 (28%) patients had early HCC, deﬁned as Child A
or B cirrhosis, with a solitary HCC or ≤3 nodules, each ≤3 cm. Of these,
53 (69.7%) received curative treatment. Thirty six percent of patients with
non-early HCC received curative treatment. Compared to patients with
non-early HCC who did not receive curative treatment, patients with early
HCC and curative treatment had the best survival [hazard ratio, HR = 0.19
(95% CI, 0.08–0.42)] followed by patients with advanced HCC who
received curative treatment [HR = 0.37 (95% CI, 0.22–0.64)]. Baseline
performance status was signiﬁcantly associated with receipt of curative
treatment as well as survival after adjusting for demographics, clinical
characteristics, and HCC stage.
Conclusions
In this multicenter database, most of the patients with early HCC received
potentially curative treatment. However, only 28% of patients had early
HCC. One-third of patients with non-early HCC also underwent curative
therapy. Potentially curative treatment improved survival and this effect
was seen in patients with early as well as non-early HCC.
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INTRODUCTION
The incidence of hepatocellular cancer (HCC) has
increased by more than two-fold over the past two
decades.1, 2 Most of this increase is attributed to hepatitis
C virus (HCV) infection acquired 2–3 decades earlier.1 A
large number of HCV-related HCCs are expected in the
next decade given that approximately 3.0 million individ-
uals are HCV infected in the United States.3
The prognosis of advanced HCC is poor.4–6 However
several potentially curative treatment modalities are
available for patients with early stage HCC. These
include surgical resection, liver transplantation, and local
ablation. Surgical resection is the primary therapeutic
option for patients without advanced cirrhosis and with
well-preserved liver function and normal portal pressure.
Among candidates who receive resection, 5-year survival
can exceed 50%.4, 7–11 Liver transplantation is the treat-
ment of choice for HCC patients with decompensated
cirrhosis, with 5-year recurrence free survival close to
70%.12 Potential contraindications to liver transplanta-
tion include presence of systemic co-morbidities, and
current drug and/or alcohol use. For patients who are
not candidates for surgical treatment, local tumour abla-
tion treatments can be used to destroy the tumour with-
out damaging the surrounding liver tissue. These tumour
ablation therapies include injection of the tumour with
absolute ethanol or radiofrequency ablation. The 5-year
survival among patients with compensated cirrhosis and
HCC smaller than 5 cm who were treated with local
ablation may be as high as 50%.7, 13, 14
There is a paucity of data evaluating the extent, pat-
terns, and outcomes of potentially curative treatment in
patients with HCC in the United States. This informa-
tion is important not only for understanding the diffu-
sion of this practice but also in determining potential
effectiveness of HCC surveillance programs—programs
that rely heavily on availability and timely application of
curative treatments in patients with early HCC.
Using data from a prospective cohort of patients with
HCC, we sought to measure the extent to which patients
with HCC received potentially curative treatment and
investigated whether use of such treatment improved sur-
vival. We also determined the factors associated with receipt
of potentially curative treatment among patients with HCC.
MATERIALS AND METHODS
Data Source
We used prospectively collected data from the Liver
Cancer Research Network (LCRN), a group of 11
medical centers throughout the United States experi-
enced in the care of patients with liver disease. The 11
centers participating in the LCRN were Beth Israel
Deaconess Medical Center, Loyola University Medical
Center, Mayo Clinic in Rochester, Oregon Health &
Science University, Saint Louis University, University of
Michigan, University of Chicago, University of Southern
California, University of California in San Diego, Long
Beach Veteran Affairs Medical Center, and Vanderbilt
University Medical Center.
Patients with HCC were enrolled if they were seen at
any of the participating centers between 20 January 2001
and 14 September 2007. The diagnosis of HCC was
based on histopathology, and if histopathology was not
available, by a mass lesion on imaging with AFP levels
>1000 ng/mL, a mass lesion with characteristics of HCC
(hypervascularity, arterial to portal vein shunts, portal
vein thrombosis near the defect, or tumour in the portal
vein) on two liver imaging studies, or 1 additional imag-
ing study showing a mass lesion with characteristics of
HCC that either increased in size over time or was
accompanied by AFP level >200 ng/mL and more than
tripling of baseline value.
After patient consent, standardized data collection
forms were used to collect sociodemographic, risk factor,
liver disease, tumour, and treatment characteristics-
related information. Patients were followed longitudinally
at 6 months intervals. Tumour and treatment parameters
were recorded during each follow up visit.
Study sample
Our study sample comprised of patients diagnosed with
HCC with at-least one follow up visit during the study
period. We categorized patients on the basis of Barcelona
Center Liver Cancer (BCLC) staging.5 We deﬁned early
stage HCC as Child Class A or B, with a solitary HCC
that was <5 cm in size, or up to 3 nodules, each <3 cm
in size. We excluded patients if they did not have data
to allow estimation of the BCLC stage. The BCLC stag-
ing system incorporates information regarding perfor-
mance status in classifying the stage of HCC. We
removed performance status criterion in ascertaining
stage of HCC because we wanted to examine the inde-
pendent effect of this variable on the receipt of curative
treatment as well as patients’ long term outcomes. How-
ever, as a sensitivity analysis, we strictly followed the
BCLC system and classiﬁed patients with limited perfor-
mance status as non-early HCC. In another analysis, we
re-classiﬁed patients as eligible for potentially curative
therapy if they met the University of California, San
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Francisco (UCSF) expanded criteria deﬁned as evidence
of single lesion  6.5 cm or up to 3 lesions, none larger
than 4 cm, with a maximum combined tumour bulk of
 8 cm.15 Patients with any evidence of extra-hepatic
spread or vessel involvement were excluded from early
stage group regardless of their local tumour burden.
Study outcomes
We deﬁned a patient as having received potentially
curative treatment if s/he received liver transplantation,
surgical resection (wedge resection, segmental resection,
lobectomy), or tumour ablation (alcohol injection abla-
tion and radiofrequency ablation) during follow up. We
deﬁned patients’ index date as the date of ﬁrst diagnosis
of HCC. We followed all participants longitudinally and
terminated the follow-up at either the time of the
patient’s death or 14 September 2007, whichever
occurred ﬁrst.
Statistical analysis
We analyzed patient data using SAS, version 9.2 (SAS
Inc., Cary, NC, USA). All P-values were two-sided using
an alpha of 0.05. We used ANOVA to compare means
between groups and used chi-square or Fisher’s Exact
tests to compare proportions. We expected to see a
strong association between the stage of HCC and
survival. Therefore, to examine the relationship between
curative treatment and survival, we used an interaction
term for this variable (receipt vs. non-receipt of
potentially curative treatment) and a binary variable
indicating early vs. non-early HCC using bivariate Cox
proportional-hazards model. We next measured the
independent relationship between curative treatment and
survival while adjusting for the following predictors at
baseline: age, gender, race, liver disease severity (as
measured by presence of ascites and baseline values of
bilirubin and albumin), presence of medical comorbidity,
performance status, and HCC volume of the treating
center. Based on centers’ self-reported data regarding the
annual number of unique HCC patients seen, we catego-
rized each center as high (>100 patients) vs. medium-
low volume (<100 patients) center. Table 1 speciﬁes the
deﬁnitions and categorization of other variables. We did
not include MELD score in our analysis because it was
missing in 60% of our patients (data collection for the
study preceded introduction of MELD score as a prog-
nostic marker for liver transplant allocation in the US).
We computed the adjusted hazard ratios (HR) and 95%
CI to estimate the strength of association of each
predictor with time to death. Using multivariate logistic
regression analysis, we determined whether and to what
extent patient demographic (age, sex, race), liver disease
characteristics (liver disease severity), medical co-mor-
bidity, performance status, and treating facility character-
istics (medical center volume) were associated with
receipt of potentially curative treatment among patients
with HCC, while adjusting for stage of cancer. To
determine if the pre-speciﬁed covariates had differential
impact on treatment decisions in patients with early vs.
non-early HCC, we stratiﬁed the sample based on the
stage of HCC and conducted a regression analysis in
each group separately. We entered number and size of
HCC tumours as additional variables in these sensitivity
analyses. Last, we considered the possibility that we
might have classiﬁed some patients who died while
awaiting liver transplantation as untreated, where in fact
these patients received the recommended treatment
related care (i.e. referral for transplantation). In order
to address this, we re-classiﬁed patients who were
considered eligible for (but did not receive) transplanta-
tion during the study follow-up as having received the
recommended treatment related care for their HCC. We
then repeated the Cox proportional-hazards model to
examine the relationship between treatment and survival
using this new variable.
RESULTS
Sample Characteristics
The LCRN database included information on 512
patients with HCC. Of these, 302 completed at-least one
follow up and 267 had complete data to allow staging on
the basis of BCLC criteria. These 267 patients constituted
the cohort for this analysis. The mean age ±standard
deviation (SD) of eligible patients was 59 ± 10 years,
and 76% were male. Seventy seven percent were White,
10% African American, and 10% belonged to other racial
groups (Table 1). The most common etiologies for liver
disease included viral hepatitis (62.6%), alcohol-related
liver disease (11.9%), and metabolic or cryptogenic liver
diseases (8.2%). At baseline, 36% had moderate-to-severe
ascites, 8.6% had at-least one medical comorbidity,
21.4% was smokers, and approximately 67% used alco-
hol. Fifty one percent of patients had normal perfor-
mance status (deﬁned as Eastern Cooperative
Performance Status16 grade 0) and approximately 37%
were seen in high volume centers.
Seventy six (28%) patients had early stage HCC on
the basis of BCLC criteria. Patients with early HCC
were less likely to have ascites (28.9% vs. 38.7%) and
Aliment Pharmacol Ther 2012; 36: 257-265 259
Published 2012. This article is a US Government work and is in the public domain in the USA.
Potentially curative treatment in HCC
more likely to have serum bilirubin value  3 mg/dL
(97.4% vs. 81.7%) than those with non-early HCC.
High volume centers were more likely to see early
HCC than medium-low volume centers (47.4% vs.
32.9%). One hundred and nine (40.8%) patients met
the UCSF expanded criteria.
Table 1 | Baseline demographic and clinical characteristics of 276 patients with early and advanced hepatocellular
cancer (HCC) who had at-least one follow up visit
Total
(N = 267)
Early HCC
(N = 76)
Not early
HCC (N = 191) P-value
Demographic characteristics
Age, % 0.07
<60 148 (55.4) 49 (64.5) 99 (51.8)
60–70 67 (25.1) 17 (22.4) 50 (26.2)
>70 48 (18.0) 8 (10.5) 40 (20.9)
Missing 4 (1.5) 2 (2.6) 2 (1.1)
Gender, % 0.94
Male 203 (76.0) 58 (76.3) 145 (75.9)
Race, % 0.88
Caucasian 205 (76.8) 59 (77.6) 146 (76.4)
African American 27 (10.1) 8 (10.5) 19 (10.0)
Other* 27 (13.1) 9 (11.9) 26 (13.6)
Clinical characteristics, %
Etiology of liver disease 0.28
Viral hepatitis 167 (62.6) 57 (75.0) 110 (57.6)
Non-viral hepatitis 57 (21.3) 15 (19.7) 42 (22.0)
Missing 43 (16.1) 4 (5.3) 39 (20.4)
Liver disease severity
Ascites (Yes) 96 (36.0) 22 (28.9) 74 (38.7) 0.057
Ascites (No) 158 (59.1) 54 (71.1) 104 (54.5)
Missing 13 (4.9) 0 13 (6.8)
Bilirubin, mg/dL 0.002
≤3.0 230 (86.1) 74 (97.4) 156 (81.7)
>3.0 30 (11.3) 2 (2.6) 28 (14.7)
Missing 7 (2.6) 0 7 (3.6)
Albumin, mg/dL 0.89
≤3.0 77 (28.8) 22 (28.9) 55 (28.8)
>3.0 184 (68.9) 54 (71.1) 130 (68.1)
Missing 6 (2.3) 0 6 (3.1)
Medical comorbidity 23 (8.6) 9 (11.8) 14 (7.3) 0.23
Smoker 57 (21.4) 16 (21.1) 41 (21.5) 0.94
Alcohol use 0.07
None 78 (29.2) 14 (18.4) 64 (33.5)
0–40 g/day 77 (28.9) 24 (31.6) 53 (27.7)
>40 g/day 101 (37.8) 33 (43.4)) 68 (35.6)
Missing 11 (4.1) 5 (6.6) 6 (3.2)
Performance status,† % 0.07
Normal 137 (51.3) 46 (60.5) 91 (47.6)
Limited 126 (47.2) 30 (39.5) 96 (50.3)
Missing 4 (1.5) 0 4 (2.1)
Site volume, % 0.02
High 99 (37.1) 36 (47.4) 63 (32.9)
Medium or low 168 (62.9) 40 (52.6) 128 (67.1)
P-values are comparisons of patients with early HCC vs. non-early HCC. Bold face P-values indicate signiﬁcance at alpha of 0.05.
* Other race includes Hispanic, Asian, Indian (subcontinent), African, Paciﬁc Islander, Native American, Alaskan Native/Aleut or
unknown.
† Performance status was assessed on the basis of Eastern Cooperative Performance Status (ECOG) classiﬁcation. ECOG status
0 means that the patient is fully active, able to carry on all activities without restriction.
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Compared to patients without any follow up, those with
at-least one follow up (study cohort) were more likely to be
White (76% vs. 60%), less likely to have ascites (35.4% vs.
41.4%), and more likely to have serum bilirubin value
greater than 3 mg/dL (84.4% vs. 76.7%) or limited perfor-
mance status (45.4% vs. 54.8%). There were no signiﬁcant
differences between patients with and without follow-up in
regards to age, gender, comorbidity, and stage of HCC
(BCLC stage and UCSF status) (data not shown).
Rate of potentially curative treatment
During a mean follow up of 448 ± 501 days, 11
(14.5%), 23 (30.3%), and 30 (39.5%) patients with early
stage HCC underwent surgical resection, tumour
ablation, and liver transplantation (Table 2). Overall, 53
(69.7%) patients with early HCC received any poten-
tially curative treatment. In contrast, 27 (14.1%), 33
(17.3%), and 22 (11.5%) patients without early stage
HCC received surgical resection, tumour ablation, and
liver transplantation, respectively.
Association between receipt of potentially curative
treatment and survival
One hundred and nineteen (39.4%) patients died dur-
ing the study follow up. Figure 1 displays the results
of the bivariate Cox-proportional hazard models. We
divided the patients into four groups: those with
(i) early stage HCC with curative treatment; (ii) early
stage HCC without curative treatment; (iii) non-early
stage HCC with curative treatment, or (iv) non-early stage
HCC without curative treatment. Appendix S1 displays
the baseline characteristics stratiﬁed by these four
groups.
Patients with non-early stage HCC who did not
receive any potentially curative treatment had the low-
est survival rate; 1- and 2-year survival rates for these
patients were 44.5% and 28.8%, respectively. Compared
with this group, likelihood of survival was substantially
higher for patients with early HCC and curative
treatment [1- and 2-year survival rates = 88.2% and
81.0%; HR for mortality = 0.14 (95% CI, 0.07–0.30)]
and those with non-early HCC who received
potentially curative treatment [1- and 2-year survival
rates = 70.7% and 59.6%; HR for mortality = 0.37
(95% CI, 0.23–0.59)]. The survival rates of patients
with early HCC who did not receive any curative
treatment did not signiﬁcantly differ from those with
non-early HCC and no curative treatment [1- and
2-year survival rates = 65.2% and 33.5%; HR for
mortality = 0.72 (95% CI, 0.37–1.40)].
The results did not change after adjustment for age,
gender, race, medical comorbidity, functional status, and
stage of liver disease in the multivariable Cox propor-
tional hazards model (Table 3) nor in the sensitivity
analyses that classiﬁed patients based on the UCSF
criteria (Appendix S2), In addition, there was no change
when strictly following BCLC criteria (by including per-
formance status in the estimation of BCLC stage), or
using alternative deﬁnition for HCC treatment care (by
including patients who were considered eligible for, but
who did not receive liver transplantation, in the treated
groups) (Appendix S3).
Table 2 | Proportion of
patients with early or non-
early HCC receiving each of
the potential curative
treatments for hepatocellular
cancer
Treatment, %
Total
(N = 267)
Early HCC
(N = 76)
Non-early
HCC (N = 191) P-value
Surgical resection 38 (14.2) 11 (14.5) 27 (14.1) 0.9432
Tumour ablation 56 (21.0) 23 (30.3) 33 (17.3) 0.0187*
Liver transplantation 52 (19.5) 30 (39.5) 22 (11.5) <0.0001*
Any potentially curative treatment 122 (45.7) 53 (69.7) 69 (36.1) 0.0001*
Surgical resection includes wedge resection, segmental resection, and lobectomy.
Tumour ablation includes alcohol injection ablation and radiofrequency ablation.
Any curative treatment includes any of the above three treatment methods. Of note, some
patients received more than one potentially curative treatment. Therefore, the numbers
presented in the individual cells do not add up to the total number of patients included in
the last cell for each column.
Among 145 patients who did not receive curative therapies (surgical resection, tumour
ablation, or liver transplant), 41 (28.3%) were treated with other modalities. Most of these
patients received TACE (n = 31). Sorafenib was not available for clinical use during the
data collection phase of the study.
P-values are comparisons of patients with early HCC vs. non-early HCC.
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Figure 1 | Results of the Bivariate Cox-proportional Hazard Models. We divided patients into four groups: those with
(i) early stage HCC with curative treatment; (ii) early stage HCC without curative treatment; (iii) non-early stage HCC
with curative treatment or (iv) non-early stage HCC without curative treatment. Early stage deﬁned as Child Class A
or B, with a solitary HCC that was  5 cm in size, or up to 3 nodules, each  3 cm in size. The data are truncated at
700 days.
Table 3 | Hazard ratio for variables associated with survival in Cox multivariate proportion hazards model
Variables Hazard ratio 95% CI P-value
Curative treatment by HCC stage*
Non-early HCC without curative treatment Reference
Early HCC with curative treatment 0.19 0.08–0.42 <0.0001
Early HCC without curative treatment 0.88 0.43–1.77 0.71
Non-early HCC with curative treatment 0.37 0.22–0.64 0.0004
Demographics
Age in years
<60 Reference
60–70 0.76 0.46–1.27 0.29
>70 1.39 0.80–2.42 0.24
Male 0.82 0.49–1.38 0.47
Race
White Reference
Black 0.78 0.36–1.69 0.54
Other race 1.20 0.63–2.24 0.57
Clinical characteristics
Medical comorbidity 1.62 0.82–3.18 0.15
Presence of ascites 1.23 0.77–1.98 0.37
Bilirubin, ≤3.0 mg/dL 0.69 0.37–1.28 0.24
Albumin, ≤3.0 mg/dL 1.51 0.92–2.47 0.09
Normal performance status (ECOG† = 0) 0.62 0.40–0.98 0.04
High volume site 0.90 0.57–1.43 0.66
Bold face indicate signiﬁcance at alpha of 0.05.
We excluded patients with missing values on independent variables from the model.
* Early stage deﬁned as Child Class A or B, with a solitary HCC that was  5 cm in size, or up to 3 nodules, each  3 cm in
size.
† Based on the Eastern Cooperative Performance Status (ECOG).
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Patients with normal performance status were 38%
less likely to die than those with compromised perfor-
mance status after adjusting for patient demographics,
clinical characteristics, as well as stage and treatment of
HCC (Table 3).
Factors associated with receipt of potentially curative
treatment in patients with HCC
As expected, the odds of receiving potentially curative
treatment were signiﬁcantly higher in patients with early
HCC than those with non-early HCC (OR = 4.44, 95%
CI = 2.34–8.42) (Table 4). In addition, patients with nor-
mal performance status had a 2-fold higher odds of receiv-
ing curative treatment than those with compromised
performance status (OR = 2.16, 95% CI = 1.19–3.91).
In the sensitivity analyses, we found a similar (and
perhaps stronger) association between performance sta-
tus and receipt of curative therapy in the sub-group of
patients with non-early HCC (OR = 3.08, 95%
CI = 1.41–6.70) but not in patients with early HCC
(Appendix S4). In addition, the odds of receiving poten-
tially curative treatment decreased as the tumour size
increased in both sub-groups (with early and non-early
HCC) (Appendix S4). Patients with early HCC seeking
care in high volume facilities had an approximately
5-fold higher odds of receiving curative treatment than
those seen in medium to low volume facilities
(OR = 4.88, 95% CI = 1.11–21.40).
DISCUSSION
In this large multicenter observational study, less than
one-third of patients with HCC were diagnosed at an
early stage. Consistent with other studies, patients with
early HCC who underwent potentially curative treatment
had excellent survival.4, 7, 9–11, 13, 14 However, only 70%
of patients with early disease received potentially curative
treatment. Although we could not ascertain whether and
to what extent patients in our study received surveillance
for HCC prior to their diagnosis, given that the data rep-
resent patients seen in centers with specialized expertise
in management of HCC patients, these estimates likely
represent the maximum beneﬁt that can be expected
from the current practice of HCC surveillance and treat-
ment. Indeed, an analysis of Surveillance, Epidemiology,
and End Results registry showed that 21% of patients
with small, non-metastatic HCC received liver transplan-
tation.17 Another study limited to 65 years and older
Medicare population found that 34% of patients with
early HCC (deﬁned as patients with single lesions or
those with lesions <3 cm) received any potentially cura-
tive treatment.18 Our data show that, in the best case
scenario, these rates can be twice as high as reported in
these population based studies, and thus provide the
upper boundary of the potential effect of HCC surveil-
lance and treatment—data that are relevant in counsel-
ing patients regarding chances of treatment receipt and
outcomes, in conducting cost-effectiveness analyses, and
in guiding policies regarding HCC surveillance in the
vulnerable cohort of patients at risk for HCC.
We also found that 36% of patients who were not candi-
dates for curative treatment based in the staging system
received curative treatment and that these patients had sig-
niﬁcantly improved survival compared to patients without
such treatment. Although there is no one universally
accepted HCC staging system, many have adopted the
BCLC system, and we used this system to stratify our
patients for this study. The goal of BCLC (and other stag-
ing systems) is to predict patients’ outcomes and to tailor
therapy in order to maximize overall effectiveness of treat-
ment. In our study, stage of HCC was the strongest driver
of treatment decisions—and hence the prognosis of
Table 4 | Factors associated with receipt of curative
treatment in patients with hepatocellular cancer
(N = 267). Results are derived from multivariate
logistic regression analyses
Variables Odds ratio 95% CI P-value
Demographics
Age in years
<60 Reference
60–70 1.08 0.56–2.11 0.65
>70 0.87 0.38–1.97 0.65
Male 0.82 0.41–1.61 0.56
Race
White Reference
Black 0.68 0.26–1.77 0.67
Other race 0.71 0.28–1.83 0.78
Clinical Characteristics
Medical comorbidity 1.24 0.44–3.51 0.68
Presence of ascites 0.74 0.38–1.45 0.38
Bilirubin,  3.0 mg/dL 0.51 0.20–1.30 0.16
Albumin,  3.0 mg/dL 1.05 0.52–2.14 0.87
Normal performance
status (ECOG* = 0)
2.16 1.19–3.91 0.01
Early stage HCC† 4.44 2.34–8.42 <0.0001
High volume site 1.57 0.86–2.87 0.14
* Based on the Eastern Cooperative Performance Status
(ECOG).
† Early stage deﬁned as Child Class A or B, with a solitary
HCC that was  5 cm in size, or up to 3 nodules, each
 3 cm in size.
Bold face indicate signiﬁcance at alpha of 0.05.
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patients. Nonetheless, we found that physicians frequently
crossed these stage-speciﬁc boundaries to extend curative
treatment to patients with more advanced HCC. Our
results suggest that this decision, at least in part, is guided
by the general health of the patient. Speciﬁcally, we found
that patients with advanced HCC but with well-preserved
performance status were 4-fold more likely to receive cura-
tive treatment compared to those with compromised per-
formance status. These patients with non-early HCC, when
treated, had modest improvement in their survival. Collec-
tively these data suggest that physicians might be using the
correct heuristic in identifying candidates for curative treat-
ment and that this heuristic might tap into aspects of
underlying risk or disease severity that are not fully cap-
tured by staging alone. We found that performance status
provides important prognostic information in patients with
HCC that goes beyond the information furnished by clini-
cal and tumour burden variables used in routine practice.
Our data, therefore, provide a compelling rationale for
incorporating formal evaluation of patients’ performance
status into clinical decision-making in patients with HCC.
We also found that individual centers might vary in
how they manage patients with early HCC. Patients with
early HCC who were seen in high volume centers were
signiﬁcantly more likely to receive a potentially curative
treatment than those seen in low-medium volume
centers after controlling for patient-related variables.
However, due to the limited sample size in this sub-
group, our estimates may not be optimally reliable and
thus should be interpreted with caution. Despite this,
our data provide preliminary insight into the likely
importance of center effect in explaining the variation in
treatment rates among patients with early HCC.
There are several other possible explanations for lack of
curative treatment in the 30% of patients with early HCC
who did not receive such treatment. It is plausible that
despite being in the ‘early’ HCC group, patients without
curative treatment had higher tumour burden (i.e. larger
lesions, etc.) compared to those who received curative treat-
ment, and our results support this possibility (Appendix
S4). Another explanation may be presence of more
advanced liver disease and higher comorbidity—factors that
are important drivers of HCC treatment decisions. Indeed,
we found that early HCC patients who did not receive cura-
tive treatment were older, were more likely to have medical
comorbidity, and more severe liver disease than those who
received curative treatment, although these estimates were
not statistically signiﬁcant, perhaps because of power limita-
tions. Other possible explanations may include patient pref-
erence and insurance related barriers. We lacked reliable
variables to determine the role of these factors as part of this
study. Larger studies with longer follow up are needed to
conﬁrm our observations and to evaluate the impact of cen-
ter effect as well as other variables.
Our analysis has several strengths. First, we used data
from a prospectively enrolled cohort of patients with HCC
instead of using administrative databases. The study relied
on standardized criteria for HCC diagnosis that in turn
were directly derived from the available clinical practice
guidelines in HCC. As a result, we minimized any ascer-
tainment bias in classifying patients with HCC. Second, our
analysis used data from a demographically diverse group of
patients with HCC seen in different regions of the U.S.
Third, the Liver Cancer Network database included a broad
array of data, allowing us to capture and adjust for the full
range of patient-level variables that might affect the receipt
and outcomes of treatment among treatment-eligible
patients. These included socio-demographic characteristics,
tumour-related characteristics, stage of liver disease, and
medical comorbidity, among others.
Our analysis also has potential weaknesses. The sam-
ple population constituted primarily of patients with
access to healthcare system that were seen at tertiary
care centers. Thus, as stated earlier, our results are likely
biased upwards. However, our data provide the upper
limit of potential effect of current process of care in
HCC. Second, the observational nature of the study
makes it hard to draw ﬁrm causal inferences regarding
impact of curative treatment on patient survival. How-
ever, randomized controlled trials designed to determine
the effect of potentially curative treatments are not pos-
sible because of cost, feasibility, and ethical consider-
ations. Within the limitations of the study design, the
longitudinal nature of the data, ﬁnding of a strong asso-
ciation, and the temporality of the cause and effect sug-
gest that the receipt of potentially curative treatment is
causally linked to better outcomes in this geographically
diverse sample of patients with HCC. Third, due to
power limitations, estimates from the sub-group (i.e.
sensitivity) analyses may not be optimally reliable.
Future research will aim to conﬁrm these ﬁndings and
to determine the role of patient related factors using lar-
ger sample sizes and longer duration of follow-up.
In conclusion, our results suggest that survival in HCC
can be improved if it is diagnosed at an early stage and
potentially curative therapy is applied in a timely manner.
However, only 28% of patients have early stage disease at
the time of HCC diagnosis, suggesting that the most
important step to make inroads into the problem of
suboptimal outcomes in HCC may be to focus on
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implementation of routine surveillance in patients who
are at risk for HCC so that more patients are diagnosed
earlier in the course of their disease. We also found that
approximately one-third of patients with non-early stage
disease received potentially curative treatment, and that
these patients had improved outcomes. Evidence based
modiﬁcations in HCC staging algorithms and routine
incorporation of performance status into clinical decision-
making may help achieve the goal of making treatment
more effective and cost-effective in patients with HCC.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Appendix S1. Baseline demographic and clinical char-
acteristics of 276 patients with hepatocellular cancer
(HCC) stratiﬁed by stage and treatment of HCC.
Appendix S2. Hazard ratio for variables associated
with survival in Cox multivariate proportion hazards
models using the University of California San Francisco
(UCSF) expanded guidelines to deﬁne stage of hepatocel-
lular cancer (HCC).
Appendix S3. Hazard ratio for variables associated
with survival in 2 Cox multivariate proportion hazards
models conducted as part of sensitivity analyses. Model
1 incorporated performance status information in the
estimation of BCLC stage (i.e. strictly following the
BCLC staging criteria) and evaluated receipt vs. non-
receipt of potentially curative treatment for hepatocellu-
lar cancer (HCC). Model 2 employed an alternative deﬁ-
nition of HCC treatment care (i.e. included patients who
were considered eligible for, but who did not receive
liver transplantation, in the treated groups) in addition
to strictly following the BCLC staging criteria.
Appendix S4. Factors associated with receipt of cura-
tive treatment in patients with early and non-early HCC.
Results are derived from 2 separate multivariate logistic
regression analyses for each sub group.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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